πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 76 of 173

  1. US 9789131

    Compounds and methods for treating neurological and cardiovascular conditions

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9789116

    Compositions and methods of modulating short-chain dehydrogenase activity

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9789095

    Inhibitors of calcium-activated chloride channels

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9783550

    Highly potent inhibitors of porcupine

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9782258

    Intramyocardial patterning for global cardiac resizing and reshaping

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9783515

    Radiomitigating pharmaceutical formulations

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9782472

    Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9782464

    Methods and compositions for inhibiting diseases of the central nervous system

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9783572

    Synthesis of syrbactin proteasome inhibitors

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9782347

    Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9782337

    Methods and compositions using compounds from fetal cells and tissues to improve condition of skin

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9782357

    RNAi molecule delivery platform based on single-siRNA and shRNA nanocapsules

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9775876

    Compositions and methods for CaMKII inhibitors and uses thereof

    Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9777340

    Compositions and methods for detecting human Pegivirus 2 (HPgV-2)

    Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9779497

    Measuring glomerular number from kidney MRI images

    Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9775852

    Acyclic nucleoside phosphonate diesters

    Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9770456

    Compositions comprising acidic extracts of mastic gum

    Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9770500

    S-nitrosylation of glucosylating toxins and uses therefor

    Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9770433

    Composition and method for treating tinnitus

    Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9770504

    Generating peptoid vaccines

    Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9763987

    Cyclic di-AMP induction of type I interferon

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9764305

    Geometry enhancement of nanoscale energy deposition by X-rays

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9763982

    Depletion of cancer stem cells

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9764001

    Target for diagnosis and treatment of diabetes and cardiovascular diseases

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9765027

    Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9765066

    Selective HDAC1 and HDAC2 inhibitors

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9765099

    STAT6 inhibitors

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9765302

    Compositions and methods for differentiating stem cells into cell populations comprising beta-like cells

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9763984

    Methods for production of platelets from pluripotent stem cells and compositions thereof

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9765337

    Phosphoribosyl pyrophosphate synthetase 2 (PRPS2) as a therapeutic target in cancer treatment

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9764953

    Peptoids useful for the mineralization of apatite

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9757379

    Inhibition of HIF-2Ξ± heterodimerization with HIF1Ξ² (ARNT)

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9759731

    Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9758775

    TAL effector-mediated DNA modification

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9757472

    Proteas stabilized antibacterial peptides for S. aureus

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9757354

    Therapeutic formulations and methods

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9758591

    Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9757468

    Intranasal administration of guanidinylated aminoglycosides

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9758555

    Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9757353

    Methods of inducing anesthesia

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9758556

    Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9750708

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9752118

    Method of directed differentiation producing corneal endothelial cells from neural crest stem cells by PDGFB and DKK2, compositions thereof, and uses thereof

    Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9750849

    Oxygen generating biomaterial

    Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9750705

    Agents useful for treating obesity, diabetes and related disorders

    Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9751970

    Block copolymer and micelle compositions and methods of use thereof

    Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9744194

    Methods of treating ischemic spasticity

    Expires Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9744141

    Multifunctional nanoparticle designs and applications

    Expires Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.